دورية أكاديمية
Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.
| العنوان: | Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. |
|---|---|
| المؤلفون: | Bekiari, Eleni, Kitsios, Konstantinos, Thabit, Hood, Tauschmann, Martin, Athanasiadou, Eleni, Karagiannis, Thomas, Haidich, Anna-Bettina, Hovorka, Roman, Tsapas, Apostolos |
| بيانات النشر: | BMJ //dx.doi.org/10.1136/bmj.k1310 |
| سنة النشر: | 2018 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | Diabetes Mellitus, Type 1, Humans, Hyperglycemia, Hypoglycemia, Outpatients, Pancreas, Artificial, Patient Safety, Randomized Controlled Trials as Topic |
| الوصف: | OBJECTIVE: To evaluate the efficacy and safety of artificial pancreas treatment in non-pregnant outpatients with type 1 diabetes. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, Cochrane Library, and grey literature up to 2 February 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials in non-pregnant outpatients with type 1 diabetes that compared the use of any artificial pancreas system with any type of insulin based treatment. Primary outcome was proportion (%) of time that sensor glucose level was within the near normoglycaemic range (3.9-10 mmol/L). Secondary outcomes included proportion (%) of time that sensor glucose level was above 10 mmol/L or below 3.9 mmol/L, low blood glucose index overnight, mean sensor glucose level, total daily insulin needs, and glycated haemoglobin. The Cochrane Collaboration risk of bias tool was used to assess study quality. RESULTS: 40 studies (1027 participants with data for 44 comparisons) were included in the meta-analysis. 35 comparisons assessed a single hormone artificial pancreas system, whereas nine comparisons assessed a dual hormone system. Only nine studies were at low risk of bias. Proportion of time in the near normoglycaemic range (3.9-10.0 mmol/L) was significantly higher with artificial pancreas use, both overnight (weighted mean difference 15.15%, 95% confidence interval 12.21% to 18.09%) and over a 24 hour period (9.62%, 7.54% to 11.7%). Artificial pancreas systems had a favourable effect on the proportion of time with sensor glucose level above 10 mmol/L (-8.52%, -11.14% to -5.9%) or below 3.9 mmol/L (-1.49%, -1.86% to -1.11%) over 24 hours, compared with control treatment. Robustness of findings for the primary outcome was verified in sensitivity analyses, by including only trials at low risk of bias (11.64%, 9.1% to 14.18%) or trials under unsupervised, normal living conditions (10.42%, 8.63% to 12.2%). Results were consistent in a subgroup analysis both for single ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | Electronic; application/pdf |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/276261Test |
| DOI: | 10.17863/CAM.23542 |
| الإتاحة: | https://doi.org/10.17863/CAM.23542Test https://www.repository.cam.ac.uk/handle/1810/276261Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.A5F7AA7E |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.23542 |
|---|